Company news

Fulcrum Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform

May 20, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results

May 12, 2020

Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference

May 10, 2020

Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8: 00 a.m. ET

May 6, 2020

Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease

April 12, 2020

Fulcrum Therapeutics Provides Business Update on Impact of COVID-19

April 1, 2020

Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

March 23, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results

March 4, 2020

Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020

February 27, 2020

Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

February 25, 2020

Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio

January 28, 2020

Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

January 5, 2020

Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

November 13, 2019

Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019

November 5, 2019

Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD

October 3, 2019

Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting

September 30, 2019

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.